Investments
3Portfolio Exits
2Funds
1Partners & Customers
10About Pierre Fabre
Pierre Fabre is a French pharmaceutical group. Founded and its headquarters still based in the South-west of France, Pierre Fabre has branches in countries and distribution agreements in over 130 countries. Covering all aspects of healthcare, from prescription drugs and OTC products to dermo-cosmetics, Pierre Fabre Laboratories employ over 10,000 people worldwide.

Want to inform investors similar to Pierre Fabre about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Pierre Fabre News
Jan 18, 2023
flora" of data A digitized library of 1,600 chemically-diverse plant extracts that can be of potential use in biological studies and future drug discovery GigaScience Researchers at the University of Geneva have established a searchable library of spectra and molecules found in a collection of 1,600 plant extracts. This collection was accessed through a collaboration with Pierre Fabre Laboratories. The resulting open resource, published in the journal GigaScience , shares both the obtained data and the employed methods. This will be useful for research ranging from drug discovery to the large-scale exploration of plants' chemical diversity. Plant metabolites play a fundamental role in drug development, as they can display potent biological activities; many existing drugs are used either as pure natural products (for example the anti-malarial artemisinin and anti-cancer drug taxol), or derived from natural products (such as the anti-cancer drugs vinorelbine, brentuximab vedotin). Pierre Fabre Laboratories have always been keen to share its pharmaceutical experience with academia. For instance, the anti-cancerous semi-synthetic natural product vinorelbine, which is derived from the Madagascar Periwinkle (Catharanthus roseus), was marketed in 1989 as a result of a collaboration with Professor Pierre Potier from the French National Center for Scientific Research (CNRS). Pierre Fabre Laboratories have made plant research a central aspect of its approach since its creation. A collection of plant samples was constituted over the 1998-2015 period with the main goal of finding novel anti-cancer drugs. This collection of botanical samples is one of the largest private plant libraries in the world numbering over 17,000 unique samples, including some rare species and covers a diverse range of botanical families from all over the world. Since 2015, Pierre Fabre Laboratories have opened access to their private plant samples collection for interested partners. This new study published in GigaScience reports the chemical characterization of circa 10% of the plant extracts in the Pierre Fabre Laboratories collection. This represents an important step towards making the chemical diversity of the full collection accessible to researchers around the world. The researchers at the University of Geneva used high-resolution mass spectrometry in combination with advanced computational pipelines to acquire over two million spectra and associated chemical information, providing valuable insights into the biochemical content of the plant extracts. The mass spectrometry profiles and associated metadata have been shared openly through the MassIVE repository (accession number MSV000087728), and this Data Note provides demonstrations on how to query this extensive curated resource. The Data Note shares both the resulting data and the employed methods, allowing for reproducibility, further exploration of the dataset and improvement of the proposed computational tools and methods. This is an exceptional resource for advancing the field of large-scale chemodiversity digitization. Such fruitful partnership between academia and industry illustrates that the fate of a historical and private collection of plant samples can be changed and that the richness of the associated chemical diversity can be made available to a wider public. Further Reading: Allard P-M et al. (2023): Open and re-usable annotated mass spectrometry dataset of a chemodiverse collection of 1,600 plant extracts. GigaScience doi: 10.1093/gigascience/giac124 Allard P-M & Wolfender, J.-L. (2021). MassIVE MSV000087728 - GNPS_PF_plant_extracts_library_dataset_01 [Data set]. MassIVE. https://doi.org/10.25345/C59J97 Allard P-M; Gaudry A; Quirós-Guerrero L; Rutz A; Dounoue-Kubo M; N Walker TW; Defossez E; Long C; Grondin A; David B; Wolfender J (2022): Supporting data for "Open and re-usable annotated mass spectrometry dataset of a chemodiverse collection of 1,600 plant extracts." GigaScience Database. http://dx.doi.org/10.5524/102323 Funding: Swiss National Science Foundation (SNFN◦CRSII5_189 921/1) Sharing on social media? Sharing on social media? About GigaScience Press GigaScience Press is BGI's Open Access Publishing division, which publishes scientific journals and data. Its publishing projects are carried out with international publishing partners and infrastructure providers, including Oxford University Press and River Valley Technologies. It currently publishes two award-winning data-centric journals: its premier journal GigaScience (launched in 2012), which won the 2018 American Publishers PROSE award for innovation in journal publishing, and its new journal GigaByte (launched 2020), which won the 2022 ALPSP Award for Innovation in Publishing. The press also publishes data, software, and other research objects via its GigaDB.org database. To encourage transparent reporting of scientific research and to enable future access and analyses, it is a requirement of manuscript submission to all GigaScience Press journals that all supporting data and source code be made openly available in GigaDB or in a community approved, publicly available repository. About GigaScience GigaScience is co-published by GigaScience Press and Oxford University Press . Winner of the 2018 PROSE award for Innovation in Journal Publishing (Multidisciplinary), the journal covers research that uses or produces 'big data' from the full spectrum of the biological and biomedical sciences. It also serves as a forum for discussing the difficulties of and unique needs for handling large-scale data from all areas of the life and medical sciences. The journal has a completely novel publication format -- one that integrates manuscript publication with complete data hosting, and analyses tool incorporation. To encourage transparent reporting of scientific research as well as enable future access and analyses, it is a requirement of manuscript submission to GigaScience that all supporting data and source code be made available in the GigaScience database, GigaDB , as well as in publicly available repositories. GigaScience will provide users access to associated online tools and workflows, and has integrated a data analysis platform, maximizing the potential utility and re-use of data. Journal
Pierre Fabre Investments
3 Investments
Pierre Fabre has made 3 investments. Their latest investment was in Ribonexus as part of their Seed VC on September 9, 2021.

Pierre Fabre Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
9/27/2021 | Seed VC | Ribonexus | $4.7M | Yes | 3 | |
4/8/2021 | Series A | |||||
1/10/2018 | Corporate Minority |
Date | 9/27/2021 | 4/8/2021 | 1/10/2018 |
---|---|---|---|
Round | Seed VC | Series A | Corporate Minority |
Company | Ribonexus | ||
Amount | $4.7M | ||
New? | Yes | ||
Co-Investors | |||
Sources | 3 |
Pierre Fabre Portfolio Exits
2 Portfolio Exits
Pierre Fabre has 2 portfolio exits. Their latest portfolio exit was Valenza Biotech on January 05, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
1/5/2023 | Acquired | 8 | |||
Date | 1/5/2023 | |
---|---|---|
Exit | Acquired | |
Companies | ||
Valuation | ||
Acquirer | ||
Sources | 8 |
Pierre Fabre Acquisitions
2 Acquisitions
Pierre Fabre acquired 2 companies. Their latest acquisition was Igenica Biotherapeutics on May 24, 2017.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
5/24/2017 | Series E+ | $85.73M | Asset Sale | 1 | ||
1/15/2007 |
Date | 5/24/2017 | 1/15/2007 |
---|---|---|
Investment Stage | Series E+ | |
Companies | ||
Valuation | ||
Total Funding | $85.73M | |
Note | Asset Sale | |
Sources | 1 |
Pierre Fabre Fund History
1 Fund History
Pierre Fabre has 1 fund, including Pierre Fabre Fund for Innovation.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
2/3/2016 | Pierre Fabre Fund for Innovation | 1 |
Closing Date | 2/3/2016 |
---|---|
Fund | Pierre Fabre Fund for Innovation |
Fund Type | |
Status | |
Amount | |
Sources | 1 |
Pierre Fabre Partners & Customers
10 Partners and customers
Pierre Fabre has 10 strategic partners and customers. Pierre Fabre recently partnered with Erasca on November 11, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
11/30/2022 | Partner | United States | `` We are excited to work with Pierre Fabre , a leader in precision oncology , on an international collaboration to explore ERAS-007 in combination with encorafenib and cetuximab in BRAF mCRC , '' said Jonathan E. Lim , M.D. , Erasca 's chairman , CEO , and co-founder . | 2 | |
10/25/2022 | Vendor | Italy | Our partnership with Bormioli Pharma reinforces our common commitment to implement concrete and measurable actions in favour of sustainable development , an approach at the heart of our responsible innovation approach , carried with the Pierre Fabre . | 1 | |
7/5/2022 | Licensee | Switzerland | Pierre Fabre buys rights to Urovant’s vibegron Urovant Sciences has entered into an exclusive license agreement with French drugmaker Pierre Fabre to register and commercialize vibegron , trade named Gemtesa , for the treatment of overactive bladder in the European Economic Area , UK , and Switzerland , with the first right of refusal for French-speaking countries of Sub-Saharan Africa , Turkey , and certain Eastern European countries . | 1 | |
6/15/2022 | Partner | ||||
2/24/2022 | Partner |
Date | 11/30/2022 | 10/25/2022 | 7/5/2022 | 6/15/2022 | 2/24/2022 |
---|---|---|---|---|---|
Type | Partner | Vendor | Licensee | Partner | Partner |
Business Partner | |||||
Country | United States | Italy | Switzerland | ||
News Snippet | `` We are excited to work with Pierre Fabre , a leader in precision oncology , on an international collaboration to explore ERAS-007 in combination with encorafenib and cetuximab in BRAF mCRC , '' said Jonathan E. Lim , M.D. , Erasca 's chairman , CEO , and co-founder . | Our partnership with Bormioli Pharma reinforces our common commitment to implement concrete and measurable actions in favour of sustainable development , an approach at the heart of our responsible innovation approach , carried with the Pierre Fabre . | Pierre Fabre buys rights to Urovant’s vibegron Urovant Sciences has entered into an exclusive license agreement with French drugmaker Pierre Fabre to register and commercialize vibegron , trade named Gemtesa , for the treatment of overactive bladder in the European Economic Area , UK , and Switzerland , with the first right of refusal for French-speaking countries of Sub-Saharan Africa , Turkey , and certain Eastern European countries . | ||
Sources | 2 | 1 | 1 |
Pierre Fabre Team
12 Team Members
Pierre Fabre has 12 team members, including former Chief Executive Officer, Olivier Bohuon.
Name | Work History | Title | Status |
---|---|---|---|
Olivier Bohuon | Smiths Group, Shire, Smith & Nephew, Abbott, and GSK | Chief Executive Officer | Former |
Name | Olivier Bohuon | ||||
---|---|---|---|---|---|
Work History | Smiths Group, Shire, Smith & Nephew, Abbott, and GSK | ||||
Title | Chief Executive Officer | ||||
Status | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.